Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL27033104 | 1.00 | TSHR (0.69) | TSHRALDH1A1CYP1A2CYP2D6CYP2C19 | |
| Bromide SCHEMBL27033077 | 1.00 | TSHR (0.69) | TSHRALDH1A1CYP1A2CYP2D6CYP2C19 | |
| Bromide SCHEMBL711677 | 1.00 | TSHR (0.69) | TSHRALDH1A1CYP1A2CYP2D6CYP2C19 | |
| Bromide SCHEMBL3437057 | 1.00 | TSHR (0.69) | TSHRALDH1A1CYP1A2CYP2D6CYP2C19 | |
| Bromide SCHEMBL8091612 | 1.00 | TSHR (0.69) | TSHRALDH1A1CYP1A2CYP2D6CYP2C19 | |
| Bromide SCHEMBL1449856 | 1.00 | TSHR (0.69) | TSHRALDH1A1CYP1A2CYP2D6CYP2C19 | |
| Bromide SCHEMBL2854923 | 1.00 | TSHR (0.69) | TSHRALDH1A1CYP1A2CYP2D6CYP2C19 | |
| Bromide SCHEMBL5573865 | 1.00 | TSHR (0.69) | TSHRALDH1A1CYP1A2CYP2D6CYP2C19 | |
| Bromide SCHEMBL20541362 | 1.00 | TSHR (0.69) | TSHRALDH1A1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL29484169 | 0.98 | TSHR (0.71) | TSHRALDH1A1CYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11560395-B2 | Azithromycin derivatives containing a phosphonium ion as anticancer agents | RISING TIDE FOUND (CH) | 2023-01-24 | — | — | US | disclosed |
| EP-3612543-B1 | AZITHROMYCIN DERIVATIVES CONTAINING A PHOSPHONIUM ION AS ANTICANCER AGENTS | RISING TIDE FOUND (CH) | 2022-11-23 | — | — | EP | disclosed |
| US-20200131208-A1 | TRIPHENYLPHOSPHONIUM-TETHERED TETRACYCLINES FOR USE IN TREATING CANCER | RISING TIDE FOUNDATION FOR CLINICAL CANCER RESEARCH (CH) | 2020-04-30 | — | — | US | disclosed |
| EP-3612543-A1 | AZITHROMYCIN DERIVATIVES CONTAINING A PHOSPHONIUM ION AS ANTICANCER AGENTS | Rising Tide Foundation (CH) | 2020-02-26 | — | — | EP | disclosed |
| EP-3612540-A1 | TRIPHENYLPHOSPHONIUM-TETHERED TETRACYCYCLINES FOR USE IN TREATING CANCER | Rising Tide Foundation (CH) | 2020-02-26 | — | — | EP | disclosed |
| CN-110799516-A | Azithromycin derivatives containing phosphonium ions as anticancer agents | 来兴泰德基金会 | 2020-02-14 | — | — | CN | disclosed |
| WO-2019234228-A1 | BETA-AMINO-ALPHA-HYDROXYALKYLPHENYL DERIVATIVES AND THEIR USE FOR CANCER TREATMENT | RISING TIDE FOUNDATION (CH) | 2019-12-12 | — | — | WO | disclosed |
| WO-2018193117-A1 | AZITHROMYCIN DERIVATIVES CONTAINING A PHOSPHONIUM ION AS ANTICANCER AGENTS | NOVINTUM BIOTECHNOLOGY GMBH (CH) | 2018-10-25 | — | — | WO | disclosed |
| WO-2018193114-A1 | TRIPHENYLPHOSPHONIUM-TETHERED TETRACYCYCLINES FOR USE IN TREATING CANCER | NOVINTUM BIOTECHNOLOGY GMBH (CH) | 2018-10-25 | — | — | WO | disclosed |
| EP-2280935-B1 | 4-TRIMETHYLAMMONIO-BUTYRATES AS CPT2 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2014-10-15 | — | — | EP | disclosed |
| US-5334736-A | Functionalizing carbohydrate derivatives by base-induced β-eliminatiom forming bioactive derivatives containing hydroxy-diene subunits | UNIVERSITY OF TEXAS SYSTEM BOARD OF REGENTS (US) | 1994-08-02 | — | — | US | disclosed |
| US-5278171-A | Anticholesterol, antilipemic agents | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-01-11 | — | — | US | disclosed |
| EP-0506072-A1 | Novel azadecalin amides and thioamides as inhibitors of cholesterol biosynthesis | MERRELL PHARMACEUTICALS INC. (US) | 1992-09-30 | — | — | EP | disclosed |
| US-5084461-A | Anticholesterol agents | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-01-28 | — | — | US | disclosed |
| US-5021414-A | Antiestrogen | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-06-04 | — | — | US | disclosed |
| US-4904661-A | ANTIESTROGENS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-02-27 | — | — | US | disclosed |
| US-4732912-A | ANTIESTROGENS, ANTITUMOR AGENTS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-03-22 | — | — | US | disclosed |
| EP-0124369-B1 | PHENOL DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-06-24 | — | — | EP | disclosed |
| EP-0124369-A1 | Phenol derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-11-07 | — | — | EP | disclosed |
| US-3987087-A | ANTI-ULCER, NASAL PATENCY, WOUND HEALING, LABOR INDUCEMENT | THE UPJOHN COMPANY (US) | 1976-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131208-A1 | TRIPHENYLPHOSPHONIUM-TETHERED TETRACYCLINES FOR USE IN TREATING CANCER | TET1, PHOSPHO1, TET3 | TSHR 1922/4885ALDH1A1 4170/4885CYP1A2 4220/4885 |
| US-11560395-B2 | Azithromycin derivatives containing a phosphonium ion as anticancer agents | NUP205, PHPT1, PHOSPHO1 | TSHR 3313/4885ALDH1A1 4622/4885CYP1A2 4605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.